Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 in Metastatic Gastric Cancer
NCT00068380Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastric cancer (GC), sponsored by National Cancer Institute. Primary endpoints: Response Rate up to 6 years, Toxicity Summary and 4 more. Started Mar 2004; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00068380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068380.